

THIS YEAR'S ACHIEVEMENTS



PERSONALIZED SUPPORT FOR MEMBERS

Our community has grown to nearly 200 members from around the globe, each navigating a unique liposarcoma journey.

Every new member receives personalized guidance and resources needed to understand the complexities of this rare disease. This support ensures that individuals can face their diagnosis with greater clarity and confidence.

EDUCATIONAL RESOURCES



In addition to up-to-date information on our website, LSN held three expert webinars this year, has scheduled our first Liposarcoma Day of Learning in February, and created a liposarcoma track at Life Fest 2026 in Nashville, TN, for patients and caregivers.

PATIENT SUPPORT GROUPS



Our support group, which meets bi-weekly, offers emotional support, practical guidance, and valuable information that helps others feel less alone and more empowered throughout their journey.



NEW MEDICAL ADVISORY BOARD

The LSN Medical Advisory Board (MAB) was formed and held its inaugural meeting on May 30, 2025, in Chicago, IL. This powerful moment officially launched collaborative work with some of the leading minds in liposarcoma care and research.



VIRTUAL TUMOR BOARD & REGISTRY

In October, we held our first Virtual Tumor Board in conjunction with The Life Raft Group, bringing together experts and clinicians to collaborate on a complex liposarcoma case. We are also preparing to launch a dedicated, global Liposarcoma Patient Registry.

ADVOCACY INITIATIVE FOR DRUG DEVELOPMENT

**SIGN
THE
PETITION**



PETITION TO CONTINUE DEVELOPMENT OF BRIGIMADLIN

While our community deeply values Boehringer Ingelheim's work in developing brigimadlin (BI 907828), a drug that has brought hope to patients with dedifferentiated liposarcoma (DDLPS), we are alarmed and profoundly disappointed by their decision to halt further development.*

*The company will continue providing the drug to patients who were already enrolled in previous brigimadlin trials but no new patients will have access.

BRIGIMADLIN IS NOT A FAILED DRUG

Although the BRIGHTLINE clinical trial for brigimadlin did not meet its primary endpoint, it delivered objective responses and prolonged disease control in a cancer with limited treatment options.

TO PATIENTS, THIS DRUG REPRESENTS HOPE

Ending further development is unacceptable and abandons patients whose lives depend on progress. This situation demands Boehringer Ingelheim pursue an alternative path: external partnerships, licensing, or academic collaborations to keep development advancing toward regulatory approval.

KEEP BRIGIMADLIN ALIVE. ACT NOW. SAVE LIVES.

